While the role of TP53 mutations in chemo-naïve colorectal cancer patients is unclear [12-14], mutant TP53 is a predictor of better clinical outcomes in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab [15]. This evidence concerns the gene TP53 and metastatic colorectal cancer.